BlossomHill Therapeutics released updated data from its Phase 1/2 SOLARA trial for BH-30643 in NSCLC patients with EGFR C797S resistance. The drug demonstrated a 45% objective response rate and 88% disease control rate in 40 evaluable patients, with a favorable safety profile showing only 9% dose reduction rates. The company plans to initiate a global Phase 2 study for this indication in Q1 2027. BlossomHill Therapeutics is a clinical-stage biopharmaceutical company developing innovative small molecule medicines for cancer treatment.

BlossomHill Therapeutics, Inc. completed its initial public offering on August 10, 2026, selling 9,375,000 shares of common stock at $16.00 per share. The transaction generated approximately $150.0 million in aggregate gross proceeds before deducting underwriting discounts and offering expenses. Concurrently, the company filed an amended and restated certificate of incorporation and adopted new bylaws effective immediately prior to the IPO closing. BlossomHill Therapeutics operates in the biotechnology industry, focusing on the discovery and development of therapeutic treatments.